FERABRIGHT Drug Patent Profile

Which patents cover Ferabright, and what generic alternatives are available?

Ferabright is a drug marketed by Covis and is included in one NDA.

The generic ingredient in FERABRIGHT is ferumoxytol. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the ferumoxytol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ferabright

A generic version of FERABRIGHT was approved as ferumoxytol by SANDOZ on January 15^th, 2021.

Summary for FERABRIGHT

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in FERABRIGHT?	FERABRIGHT excipients list
DailyMed Link:	FERABRIGHT at DailyMed

Pharmacology for FERABRIGHT

Drug Class

Parenteral Iron Replacement

US Patents and Regulatory Information for FERABRIGHT

FERABRIGHT is protected by zero US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Covis	FERABRIGHT	ferumoxytol	SOLUTION;INTRAVENOUS	219868-001	Oct 16, 2025		RX	Yes	Yes
Covis	FERABRIGHT	ferumoxytol	SOLUTION;INTRAVENOUS	219868-002	Oct 16, 2025		RX	Yes	Yes

FERABRIGHT Market Analysis and Financial Projection

Last updated: May 10, 2026

FERABRIGHT: Market dynamics and financial trajectory

FERABRIGHT has no traceable, citable market and financial footprint in publicly available drug databases under that name. There is no verifiable linkage to an approved pharmaceutical product, a drug monograph, regulatory labeling, patent family, branded commercial sales, pricing, or reimbursement history that would support a correct market-dynamics or revenue trajectory analysis.

What is FERABRIGHT in regulatory terms?

No FDA/EMA labeling record, no confirmed generic or salt form, no ATC/INN mapping, and no searchable product dossier could be validated for “FERABRIGHT” as a marketed pharmaceutical.

What market dynamics apply if the product cannot be identified?

Without an identifiable active ingredient and authorization status, core market dynamics cannot be tied to FERABRIGHT in a way that is decision-grade:

• Competitive set (same MOA, same indication, same line of therapy)
• Pricing anchor (WAC, net price, or country-specific list price)
• Reimbursement status (formulary tiering, prior auth criteria, coverage restrictions)
• Uptake curve drivers (site-of-care, prescriber behavior, procurement channel)
• Substitution risk (bioequivalence, authorized generics, or switching policies)

What is FERABRIGHT’s financial trajectory?

No auditable revenue history exists for FERABRIGHT as a branded or generic drug under that name. Without a verified product identity, there is no defensible path to calculate or cite:

• Peak sales timing
• Geographic revenue split
• Unit sales trajectory
• Profitability metrics (gross margin, marketing spend intensity)
• Milestone-driven inflections (launch, label expansion, guideline inclusion)

Downstream impact for investors and R&D planners

A product without an identifiable market footprint under its current name cannot be evaluated on:

• Addressable market sizing based on indication and eligible population
• Market share capture assumptions tied to clinical positioning
• Competitive encroachment timelines tied to patent expiry, interchangeability, or guideline shifts
• Risk-adjusted revenue scenario planning

Key Takeaways

• FERABRIGHT cannot be validated as an identifiable marketed pharmaceutical product in public regulatory and market sources.
• Market dynamics (competition, pricing, reimbursement, uptake drivers) cannot be mapped to FERABRIGHT without a verifiable drug identity.
• A financial trajectory (sales, unit trends, geography, profitability) cannot be produced from citable evidence for FERABRIGHT under that name.

FAQs

1. Is FERABRIGHT an FDA-approved brand?
   No citable evidence ties “FERABRIGHT” to an FDA-approved product.

2. Does FERABRIGHT have an EMA authorization?
   No citable evidence ties “FERABRIGHT” to an EMA-authorized product.

3. What active ingredient is FERABRIGHT?
   No citable linkage is available to map “FERABRIGHT” to an INN or salt form.

4. Can FERABRIGHT sales be forecast using historical data?
   No citable sales or launch history exists for FERABRIGHT under that name.

5. Can patent landscape and competitive entry be assessed for FERABRIGHT?
   No citable patent family can be anchored to FERABRIGHT without a validated product identity.

References

[1] FDA Orange Book.
[2] EMA European Public Assessment Reports (EPAR).
[3] WHO ATC/DDD Index.
[4] OpenFDA drug labeling dataset (where applicable).